Compare Adaptive Biotechnologies Corp (ADPT) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Monster Beverage Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Monster Beverage Corp trades at $96.03 (market cap $94.79B). The key difference: Monster Beverage Corp is far larger — about 28.5× Adaptive Biotechnologies Corp's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Adaptive Biotechnologies Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | MNST | |
|---|---|---|
Market Cap | $3.33B | $94.79B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $97.64 |
52-Week Low | $10.24 | $58.65 |
Enterprise Value | $3.19B | $93.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Monster Beverage (MNST) trades at $96.92, down 0.7% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $6.3B in 2022 to $8.3B in 2025 and net income reaching $1.91B. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.58 exceeding the $0.527 forecast. Analyst sentiment remains positive with 53% buy ratings, though valuation metrics appear elevated with a P/E of 47.04.
MNST presents growth opportunities through international expansion and product innovation, with overseas sales reaching 45% of revenue. However, the stock faces risks from premium valuation levels and competitive pressures in the energy drink market. The consensus price target of $91.67 suggests potential downside from current levels, while technical indicators show the stock trading near resistance at $98-$100.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
